A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE008 (KOR) · Dr. Kim
consented 2022-11-15
AEs
4
Serious
0
Dropout signal
–
Adverse events
severe
assessed
Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-07-31 (study day 240); relationship: not assessed
moderate
assessed
Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-12-30 (study day 392); relationship: N
moderate
assessed
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-12-06 (study day 734); relationship: Y
moderate
assessed
Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2025-01-12 (study day 771); relationship: not assessed
Data queries
No data queries.